HC Wainwright Analysts Reduce Earnings Estimates for MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – HC Wainwright lowered their Q3 2026 earnings estimates for shares of Mirum Pharmaceuticals in a report issued on Monday, October 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.05 per share for the quarter, down from their prior forecast of $0.07. HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q1 2027 earnings at $0.07 EPS, Q2 2027 earnings at $0.12 EPS, Q4 2027 earnings at $0.70 EPS and FY2027 earnings at $1.16 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The company had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same period in the prior year, the firm posted ($0.12) earnings per share. The company’s revenue was up 37.9% on a year-over-year basis.

Several other research firms also recently issued reports on MIRM. JPMorgan Chase & Co. upped their price objective on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Citigroup lifted their target price on Mirum Pharmaceuticals from $160.00 to $184.00 and gave the company a “buy” rating in a research note on Monday. UBS Group set a $137.00 target price on Mirum Pharmaceuticals in a research note on Thursday, August 27th. Royal Bank Of Canada boosted their target price on Mirum Pharmaceuticals from $135.00 to $155.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Finally, Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $146.62.

Mirum Pharmaceuticals Trading Down 7.5%

Shares of Mirum Pharmaceuticals stock opened at $79.62 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The firm has a 50 day simple moving average of $94.21 and a 200 day simple moving average of $100.88. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00.

Insider Activity

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 40,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at approximately $19,187,339.20. This trade represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 98,499 shares of company stock valued at $9,797,834. 8.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC bought a new stake in Mirum Pharmaceuticals in the second quarter valued at about $27,000. Summit Securities Group LLC acquired a new position in Mirum Pharmaceuticals in the first quarter valued at about $42,000. Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the second quarter worth about $44,000. State of Wyoming bought a new position in Mirum Pharmaceuticals during the second quarter worth about $52,000. Finally, Fifth Third Bancorp bought a new position in Mirum Pharmaceuticals during the first quarter worth about $56,000.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: LIVMARLI met the primary endpoint in the Phase 3 EXPAND study, improving cholestatic pruritus and reducing serum bile acids in patients with ultra-rare cholestatic liver diseases. Mirum plans to submit the data to the FDA in 2027, potentially expanding LIVMARLI’s commercial opportunity. Mirum’s Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
• Positive Sentiment: The positive Phase 3 results strengthen the outlook for LIVMARLI, Mirum’s key commercial product, and may support future revenue growth if regulators approve the expanded indication. Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results
• Positive Sentiment: Citigroup raised its price target to $184 from $160 and maintained a Buy rating. HC Wainwright also lifted its target to $200 and retained its Buy rating, signaling substantial long-term upside in analysts’ models.
• Neutral Sentiment: Analyst coverage remains broadly optimistic, although the consensus still projects a full-year loss of approximately $1.31 per share, underscoring that Mirum is not yet consistently profitable.
• Negative Sentiment: HC Wainwright lowered its third-quarter 2027 earnings estimate to $0.27 per share from $0.35. The cut may be weighing on the stock because it suggests a less favorable near-term earnings trajectory despite the strong clinical update.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.